Clinical trials: Cell Free DNA
- Condition Cell Free DNA
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer, Early Detection of Cancer
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
- Conditions
- Cancer, Early Detection of Cancer, Circulating Cell-free DNA
- Trial name
- PREVENT (NCT05227534)
- Testing
- OverC multi-cancer detection blood test
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Cardiac Transplant Failure, Cardiac Transplant Rejection
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- D-OAR (NCT02178943)
- Where
- 28 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CareDx
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Cancer
Pan-canceR Early DetectIon projeCT
PREDICT is a prospective, multi-center study for the early detection of pan-cancer through cell-free DNA (cfDNA) methylation based model, in which approximately 14,000 participants will be enrolled.
- Trial name
- PREDICT (NCT04383353)
- Where
- 3 sites in China
- Volunteers
- 14,026 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Gastric Cancer
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
To facilitate the early gastric cancer diagnosis, an assay based on assessing large-scale methylation and fragmentation profiles of the plasma cell free (cfDNA) will be developed and validated.
- Trial name
- NCT05668910
- Testing
- whole genomic methylation and fragmentation profile analysis of cfDNA
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
22q.11.2 Deletion/Duplication
Non-Invasive Chromosomal Evaluation of 22q11.2
This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.
- Trial name
- 22Q (NCT02541058)
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Cindy Cisneros
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00694213
- Testing
- VCL-IPM1, VCL-IPT1, PBS
- Where
- 3 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vical
Healthy
A First-in-human Trial to Assess the Safety and Performance of the BioCaptis in Healthy Volunteers
Liquid biopsy is a new field in medicine where doctors can look at small molecules in our blood, called DNA, that carry the genetic material that makes us who we are.
- Trial name
- NCT05813041
- Testing
- BioCaptis
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BioCaptiva Ltd.
Gastric Cancer
Early Detection and Post-operative Monitoring of Gastric Cancer
This study is to determine the performance of non-invasive new multi-target biomarkers in the early detection and post-operative monitoring of gastric cancer.
- Trial name
- NCT06232395
- Testing
- DNA test
- Where
- 2 sites in China
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Suzhou Huhu Health & Technology Inc.
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（PROFOUND）
This study is a multi-center, case-control study aiming at developing and blinded testing machine learning-based multiple cancers early detection model by prospectively collecting blood samples from newly diagnosed cancer…
- Trial name
- PROFOUND (NCT06217900)
- Where
- 8 sites in China
- Volunteers
- 16,666 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Colo-rectal Cancer
Plasma-based Colorectal Cancer Screening Research & Development
The objective of this Clinical Sample Collection Study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e.
- Trial name
- NCT04027790
- Testing
- Epi proColon
- Where
- 5 sites in United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Prostatic Neoplasms
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy.
- Trial name
- NCT02771769
- Testing
- blood draw
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chronix Biomedical Corporation
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Breast Cancer
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest.
- Trial name
- NCT03511859
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- CellMaxLife